SCHEMBL5100930

SCHEMBL5100930

O=C(CCl)N1CC(F)(F)C(F)(F)C1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.47
HTT P42858 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 2/20 0.39
LMNA P02545 2/20 0.37
DPP4 P27487 1/20 0.35
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
CYP3A4 P08684 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
YAP1 P46937 1/20 0.33
TEAD4 Q15561 1/20 0.33
GPX4 P36969 1/20 0.33
PRMT3 O60678 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16083080 0.86 ALDH1A1 (0.47) ALDH1A1HTTSMN1; SMN2POLBLMNA
SCHEMBL18956020 0.82 ALDH1A1 (0.48) ALDH1A1HTTSMN1; SMN2POLBLMNA
SCHEMBL22423472 0.82 ALDH1A1 (0.44) ALDH1A1HTTSMN1; SMN2POLBLMNA
SCHEMBL27012291 0.80 ALDH1A1 (0.50) ALDH1A1HTTSMN1; SMN2POLBLMNA
SCHEMBL20547329 0.80 ALDH1A1 (0.50) ALDH1A1HTTSMN1; SMN2POLBLMNA
SCHEMBL30459460 0.79 ALDH1A1 (0.41) ALDH1A1HTTSMN1; SMN2POLBLMNA
SCHEMBL24414321 0.78 ALDH1A1 (0.48) ALDH1A1HTTSMN1; SMN2POLBLMNA
SCHEMBL22146503 0.77 ALDH1A1 (0.44) ALDH1A1HTTSMN1; SMN2POLBLMNA
SCHEMBL11837217 0.76 ALDH1A1 (0.52) ALDH1A1HTTSMN1; SMN2POLBLMNA
SCHEMBL16083089 0.74 ALDH1A1 (0.50) ALDH1A1HTTSMN1; SMN2POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7439263-B2 Pyrrolidine and thiazolidine compounds LES LABORATOIRES SERVIER (FR) 2008-10-21 US disclosed
EP-1598350-B1 Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis SERVIER LAB (FR) 2007-07-11 EP disclosed
US-20050261501-A1 Pyrrolidine and thiazolidine compounds LES LABORATOIRES SERVIER (FR) 2005-11-24 US disclosed
EP-1598350-A1 Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis LES LABORATOIRES SERVIER (FR) 2005-11-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261501-A1 Pyrrolidine and thiazolidine compounds DPP4, DPP3, NR4A1 ALDH1A1 653/4885HTT 2955/4885SMN1; SMN2 2427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.